A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma

被引：0

作者：

Ikeda, Masafumi ^{[1
]}

Sung, Max W. ^{[2
]}

Kudo, Masatoshi ^{[3
]}

Kobayashi, Masahiro ^{[4
]}

Baron, Ari D. ^{[5
]}

Finn, Richard S. ^{[6
]}

Kaneko, Shuichi ^{[7
]}

Zhu, Andrew X. ^{[8
]}

Kubota, Tomoki ^{[9
]}

Kraljevic, Silvija ^{[10
]}

Ishikawa, Kohei ^{[9
]}

Siegel, Abby B. ^{[11
]}

Kumada, Hiromitsu ^{[4
]}

Young, Louise ^{[12
]}

Okusaka, Takuji ^{[13
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Chiba, Japan

[2] Tisch Canc Inst Mt Sinai, New York, NY USA

[3] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[4] Toranomon Gen Hosp, Dept Hepatol, Tokyo, Japan

[5] Pacific Hematol Oncol Associates, Calif Pacific Med Ctr, San Francisco, CA USA

[6] UCLA Med Ctr, David Geffen Sch Med, Losa Angeles, CA USA

[7] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Kanazawa, Ishikawa, Japan

[8] Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA

[9] Eisai & Co Ltd, Tokyo, Japan

[10] Eisai Ltd, Hatfield, Herts, England

[11] Merck Co Inc, Kenilworth, NJ USA

[12] Eisai Australia Pty Ltd, Melbourne, Vic, Australia

[13] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

182

引用

页码：105 / 105

页数：1

共 50 条

[1] A Phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
Ikeda, M.
Sung, M. W.
Kudo, M.
Kobayashi, M.
Baron, A. D.
Finn, R. S.
Kaneko, S.
Zhu, A. X.
Kubota, T.
Kraljevic, S.
Ishikawa, K.
Siegel, A. B.
Kumada, H.
Okusaka, T.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 37 - 37
[2] A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma
Finn, Richard
Ikeda, Masafumi
Zhu, Andrew
Sung, Max W.
Baron, Ari D.
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Shuichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Mody, Kalgi
Kubota, Tomoki
Dutcus, Corina E.
Saito, Kenichi
Siegel, Abby B.
Dubrovsky, Leonid
Llovet, Josep M.
JOURNAL OF HEPATOLOGY, 2020, 73 : S120 - S121
[3] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Ikeda, Masafumi
Sung, Max W.
Kudo, Masatoshi
Kobayashi, Masahiro
Baron, Ari David
Finn, Richard S.
Kaneko, Shuichi
Zhu, Andrew X.
Kubota, Tomoki
Kraljevic, Silvija
Ishikawa, Kohei
Siegel, Abby B.
Kumada, Hiromitsu
Okusaka, Takuji
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Llovet, Josep
Finn, Richard
Ikeda, Masfumi
Sung, Max
Baron, Ari
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Suichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Mody, Kalgi
Kubota, Tomoki
Dutcus, Corina
Saito, Kenichi
Siegel, Abby
Dubrovsky, Leonid
Young, Louise
Zhu, Andrew X.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 189 - 190
[5] A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Kudo, Masatoshi
Finn, Richard S.
Ikeda, Masafumi
Sung, Max W.
Baron, Ari D.
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Shuichi
Pracht, Marc
Meyer, Tim
Nagao, Satoshi
Saito, Kenichi
Mody, Kalgi
Ramji, Zahra
Dubrovsky, Leonid
Llovet, Josep M.
LIVER CANCER, 2024, 13 (04)
[6] Exploratory circulating biomarker analyses: lenvatinib plus pembrolizumab (L plus P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).
Zhu, Andrew X.
Llovet, Josep M.
Kobayashi, Masahiro
Ikeda, Masafumi
Pracht, Marc
Sung, Max W.
Baron, Ari David
Kudo, Masatoshi
Meyer, Tim
Okusaka, Takuji
Kumada, Hiromitsu
Kaneko, Shuichi
Hoshi, Taisuke
Saito, Kenichi
Li, Shuyu D.
Funahashi, Yasuhiro
Minoshima, Yukinori
Dubrovsky, Leonid
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma
Lee, C-H.
Makker, V.
Rasco, D.
Taylor, M.
Dutcus, C.
Shumaker, R.
Schmidt, E. V.
Stepan, D.
Li, D.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2017, 28
[8] Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Finn, Richard S.
Ikeda, Masafumi
Zhu, Andrew X.
Sung, Max W.
Baron, Ari D.
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Shuichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Kubota, Tomoki
Dutcus, Corina E.
Saito, Kenichi
Siegel, Abby B.
Dubrovsky, Leonid
Mody, Kalgi
Llovet, Josep M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (26) : 2960 - +
[9] A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck
Taylor, Matthew H.
Rasco, Drew W.
Brose, Marcia S.
Vogelzang, Nicholas J.
Richey, Stephen L.
Cohen, Allen L.
Richards, Donald A.
Stepan, Daniel E.
Dutcus, Corina E.
Guo, Matthew
Shumaker, Robert C.
Schmidt, Emmett V.
Young, Louise
Wirth, Lori J.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 174 - 174
[10] A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
Taylor, Matthew H.
Rasco, Drew W.
Brose, Marcia S.
Vogelzang, Nicholas J.
Richey, Stephen Lane
Cohn, Allen Lee
Richards, Donald A.
Stepan, Daniel E.
Dutcus, Corina E.
Guo, Matthew
Shumaker, Robert Charles
Schmidt, Emmett V.
Wirth, Lori J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →